Ocugen, Inc. has entered into a securities purchase agreement with Janus Henderson Investors to purchase 20,000,000 shares of common stock and warrants at a purchase price of $1.00 per share. The gross proceeds to the Company are expected to be approximately $20 million, with potential for up to $30 million if warrants are exercised in full. The offering is expected to close on or about August 11, 2025, subject to customary closing conditions. Ocugen is a biotechnology leader in gene therapies for blindness diseases, with programs in development for inherited retinal diseases and blindness affecting millions worldwide.

Read more at GlobeNewswire: Ocugen, Inc. Announces $20 Million Registered Direct